Scutellaria Soluble Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a water-dispersible botanical extract prepared from Scutellaria baicalensis Georgi root and standardised to baicalin (C21H18O11) content on a dried basis. The material is released under a manufacturer-specific grade code such as SP-VG-85, in which the suffix denotes the nominal baicalin assay. Unlike crude Scutellaria root powder, which is predominantly fibre and water-insoluble cell-wall material, this grade is purified, salt-adjusted, and controlled for chromatographic purity, residual solvents, elemental impurities, and, where injectable use is declared, bacterial endotoxins. The intended incorporation routes are tablet compression, injectable liquids, hard gelatin or hypromellose capsules, dry powders, granules, mineral premixes, and drinking-water solutions. A certificate of analysis for a veterinary API grade typically contains appearance, identification by HPLC-UV, baicalin assay, loss on drying, residue on ignition, pH of a diluted aqueous solution, bulk and tapped density, particle size distribution, total aerobic microbial count, and total yeast and mould count. The specification boundary that separates this soluble powder from crude botanical feedstock is not the presence of baicalin alone but the reduced insoluble residue and the ability to pass through a 0.45 µm membrane filter after reconstitution under defined pH conditions. Published data for membrane-filterability of complex veterinary premixes is limited; therefore, filterability trials are executed on each batch before injectable compounding.

Differences from non-standardised farm-grade extracts are expressed as retention-time fingerprint overlap and narrow assay intervals rather than as visible colour intensity. Baicalin assay is controlled at not less than 85.0% on dried basis by HPLC, which reduces the overage calculation required in tablet and premix formulation. This is a distinguishing feature because solvent-extracted materials standardised only by dry matter may vary in active content with harvest year and extraction temperature. The soluble powder is salt-adjusted to improve cold-water dispersion. The pH of a 1% aqueous solution is controlled within 6.0–8.0 to prevent precipitation in hard water or after contact with acidic carrier matrices. Loss on drying is controlled at not more than 5.0%, and particle size D90 is controlled at not more than 150 µm unless finer milling is ordered for inhalation or injectable trials. The product is not a premix; it is the active ingredient from which the veterinary dosage form is built.

The production route includes aqueous ethanol extraction, clarification by centrifugation and membrane filtration, concentration, salt adjustment, and spray drying. The spray-drying step is operated to an outlet temperature below 90°C to limit thermal degradation of the glucuronide. The resulting powder is discharged into polyethylene-lined drums under nitrogen overlay where residual oxygen below 2% is maintained. This level of process control is absent in crude dried herb powders and is one factor that permits reproducible dissolution in the seven listed dosage forms.

Why Does Aqueous Compounding pH Dictate Filtration and Clear Solution Stability?

In aqueous compounding, the API is not added directly to a large volume of water without pH control. Baicalin is a glucuronide with pH-dependent solubility; free acid forms are poorly wetted, whereas salt-adjusted forms disperse quickly. A stock solution is prepared by adding the powder to water at 20–30°C with continuous mixing and buffering to pH 6.5–7.5 using phosphate or citrate buffer. Below pH 4.0, the solution may become turbid because of aglycone precipitation and loss of glucuronide solubility. The reconstitution vessel should be stainless steel 316L or high-density polyethylene; unprotected carbon steel is not used because extract polyphenols can chelate iron, causing discoloration and assay loss. For injectable or ophthalmic preparations, the reconstituted solution is passed through a 0.45 µm prefilter and then a 0.22 µm sterilising-grade filter. Filter loading capacity is determined by the insoluble matter specification and the presence of any salting-out counterions. If the pH is not maintained, filter pressure increases and throughput drops. The solution is stored at 2–8°C and used within 24 h unless preservative efficacy data support longer holding times. These pH boundaries are operational limits, not merely storage conditions, because baicalin recovery after filtration falls if the solution pH is outside the controlled interval.

Dry powder and capsule processing is governed by flow behaviour rather than by dissolution rate alone. The API is first passed through a 0.5 mm conical mill or a 0.3 mm screen to disperse soft agglomerates, then blended with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and colloidal silicon dioxide. The final blend is targeted to a bulk density of 0.45–0.65 g/mL and a Carr index below 25 to support reproducible auger filling into hard capsules. If the API is not pre-dried when ambient relative humidity exceeds 60%, agglomeration and feed rate drift occur on automatic capsule machines. Granules for sachets or tablet intermediates are produced by wet granulation using a 5% povidone K30 binder solution and dried in a fluid-bed dryer at inlet air temperature not exceeding 60°C; above 60°C, the baicalin content can decline under prolonged wet heat. Dry granulation by slugging or roller compaction is preferred when the formulation contains heat-sensitive carriers. Blend uniformity is confirmed by HPLC using 10 sampling points distributed across the blender; the acceptance limit is typically 90.0%–110.0% of label claim with RSD not more than 5.0%. The granule particle size is controlled to D50 100–250 µm for tablet flow and to D90 500 µm for direct sachet filling.

For content uniformity verification, HPLC assay specificity is established using a C18 column, 250 mm × 4.6 mm, 5 µm packing, with phosphate buffer and acetonitrile mobile phase. Detection is at 277 nm. System suitability requires resolution between baicalin and baicalein of not less than 2.0 and tailing factor not more than 2.0. Calibration linearity is demonstrated from 0.05 mg/mL to 1.0 mg/mL baicalin. The method is used to release the API and to verify blend uniformity, tablet content uniformity, capsule assay, and premix concentration. A stability-indicating adaptation is applied after forced degradation with heat, acid, base, and hydrogen peroxide.

Tableting Behaviour and Dry Granulation Boundaries

Tablet compression of botanical APIs requires defined moisture and particle-size boundaries because the extract acts as a brittle, hygroscopic component. In direct compression, the API is limited to not more than 30% of the core weight unless particle coating or dry granulation is used; beyond this level, sticking to upper punches and splitting at the band have been observed. The main compression parameters are monitored on a rotary tablet press with 10–12 kN compression force for 8 mm round biconvex tooling. Tablet hardness is kept between 60 N and 90 N; lower hardness increases friability above the 1.0% limit of Ph. Eur. 2.9.7, while higher hardness can extend disintegration beyond 15 min in water at 37°C per Ph. Eur. 2.9.1. Magnesium stearate is limited to 0.5% w/w because higher levels retard aqueous penetration into the tablet matrix. Pre-drying at 40–50°C for 4–8 h is applied when the loss on drying exceeds 3.0% or when the relative humidity in the compression suite exceeds 60%. Directly compressed formulations are avoided when API particle-size D90 exceeds 150 µm; larger particles produce visible speckling and content uniformity hotspots. Dry granulation is preferred for high-dose tablets because it densifies the extract while retaining disintegration behaviour.

When Injectable Routes Require Endotoxin and Particulate Compliance

The injectable use of Scutellaria soluble powder is not identical to oral or premix use. The API is dissolved in Water for Injection at 20–30°C and adjusted to pH 6.5–7.5 with dilute sodium hydroxide or phosphate buffer, then aseptically filtered through a 0.22 µm polyethersulfone filter. The solution is filled into depyrogenated glass vials and terminally sterilised at 121°C for 15 min only if thermal degradation data show acceptable assay retention. When terminal sterilisation is not feasible, aseptic filtration under Grade A conditions is used. The API release specification for injectable batches adds bacterial endotoxins, sterility, particulate matter, and abnormal toxicity testing where required by the target species. Endotoxin content is controlled below 0.5 EU/mg to avoid pyrogen load in multi-dose injectable products. Particulate matter per vial is controlled according to Ph. Eur. 2.9.19 or USP <788>; subvisible particle counts are limited to not more than 6000 particles ≥ 10 µm and 600 particles ≥ 25 µm per container when reconstituted. Osmolality is adjusted to 280–320 mOsm/kg with sodium chloride or dextrose for parenteral administration. The product is not used directly as a dry powder for injection; it is dissolved and then sterilised by filtration. This distinguishes pharmaceutical-grade soluble powder from water-soluble extracts sold only for drinking-water application.

Premix manufacturing uses stepwise dilution rather than direct addition of concentrated API to a large mineral carrier. A 1:10 pre-blend is prepared by mixing the Scutellaria soluble powder with silica-coated limestone or corncob meal for 10 min in a ribbon mixer at 20 rpm; the pre-blend is then diluted to final concentration in a second mixing stage. Direct addition without pre-blending produces baicalin hotspots and visually yellow clusters, because the concentrated API has a stronger colour intensity than the carrier. In acidogenic premixes containing choline chloride or citric acid, local pH below 4.0 can induce baicalin precipitation and reduce measured recovery from the carrier. The premix is therefore protected by selecting neutral carriers or by adding a small mass fraction of sodium bicarbonate, not exceeding 1.0% of total premix mass, before the API is introduced. If the premix contains trace-mineral sulphates, a chelation test is performed because extract polyphenols can form coloured complexes with iron, copper, and manganese; this interaction does not always indicate assay loss but may create specification failures for appearance. The premix is stored below 25°C and 60% relative humidity in sealed woven polypropylene bags with an inner polyethylene liner. Batch-to-batch uniformity is confirmed using 20 sampling points and an HPLC acceptance range of 90.0%–110.0% of declared baicalin content.

For drinking-water solutions, the API is reconstituted as a concentrated stock solution, typically at 10 g/L baicalin equivalent, and then proportionally injected into the water line using a dosing pump. The stock solution should be prepared in a high-density polyethylene tank, kept under gentle agitation, and protected from direct sunlight. Because the extract contains organic carbon, microbial proliferation in non-preserved stock solutions is controlled by holding at 2–8°C and by discarding unused stock after 24 h. If metered dilution enters water medicated at 1:1000 to 1:5000, final water hardness should be assessed because calcium ions can reduce clarity at alkaline pH but do not necessarily reduce baicalin recovery. Mixing with strongly acidic acidifiers or oxidising disinfectants is avoided; chlorinated water above 3 mg/L free chlorine can reduce baicalin assay by oxidation. The product is not compatible with uncoated aluminium equipment due to polyphenol-mediated surface corrosion; stainless steel 316L, polypropylene, or high-density polyethylene is specified for solution contact. Published data for the stability of Scutellaria soluble powder in all regional drinking-water matrices is limited; therefore, on-farm stability trials are conducted for each water source.